USFDA rejection of Covaxin not to impact India’s Covid-19 vaccination drive
Bharat Biotech Phase-III data has been screened by the Indian regulators and would be published in the next 7-8 days, Paul said. The USFDA rejecting Bharat Biotech’s emergency use authorisation for the COVAXIN vaccine will not have any impact on the country’s Covid-19 vaccination drive. Their decision has no bearing on our programme, VK Paul, … Read more